SAN FRANCISCO, CA—Results from a Phase 3b study presented at The Liver Meeting® 2015 suggest that 3D ± ribavirin (RBV) achieved high rates of on-treatment response and was well tolerated with a low rate of discontinuation due to adverse events in hepatitis C virus (HCV) genotype 1 (GT1) infected patients.

Ombitasvir/paritaprevir/ritonavir + dasabuvir (3D) ± ribavirin (RBV) demonstrated in Phase 3 trials high SVR12 rates with a favorable safety profile in HCV GT1 patients, including those with compensated cirrhosis.

TOPAZ-I and TOPAZ-II studies are evaluating the influence of SVR12 on progression of liver disease through 5 years post-treatment in a wide range of patients receiving 3D ± RBV.

TOPAZ-II was Phase 3b, open-label, non-randomized multi-center trial held in 48 community and academic centers in patients who were treatment-naïve or interferon/RBV treatment-experienced, with or without compensated cirrhosis. Included patients had a creatinine clearance ≥30mL/min, albumin ≥2.8g/dL, and platelet count ≥25 x 109/L.  

Continue Reading

Nancy Reau, MD, from the University of Chicago Medical Center, Chicago, IL, and colleagues  analyzed the patients with GT1a infection without cirrhosis that were given 12 weeks of 3D + RBV, and patients with cirrhosis that were given 3D + RBV for 12 or 24 weeks; patients with GT1b infection received 3D ± RBV for 12 weeks.

Of the total 615 patients that received the study drug, 95.3% (586/615) achieved SVR12 with 12 or 24 weeks of treatment with 3D ± RBV (intent-to-treat [ITT] population 95% CI: 93.3, 96.7). “High SVR12 rates were achieved in all patient subgroups examined,” noted Dr. Reau. In the modified ITT (mITT) population, SVR12 rates were 97.3% (95% CI: 95.7, 98.4). 

Five patients (0.8%) experienced on-treatment virologic failure and 11 (1.9%) relapsed by post-treatment Week 12. A total of 6 patients (1.0%) stopped therapy due to adverse events, 4 of which achieved SVR12.

Treatment with 3D ± RBV resulted in high rates of on-treatment response and was well-tolerated in the TOPAZ-II study. Study patients will be followed for 5 years post-treatment to assess the long-term effect of SVR12 on progression of liver disease, added Dr. Reau.